concentrations.Methotrexate and other drugs that, like Lasix, undergo

1890669-overview ), vitamins B and CSolution: No preparation needed (available form: 10 mg/mL)Injection: Inject directly or into tubing of actively running IV over 1-2 minutesAdminister undiluted IV injections at rate of 20-40 mg/min; not to exceed 4 mg/min for short-term intermittent infusion; in children, give 0.5 mg/kg/min, titrated to effectAdding plans allows you to compare formulary status to other drugs in the same class.To view formulary information first create a list of plans. intake of Lasix and sucralfate should be separated by at least two hours.In isolated cases, intravenous administration of Lasix High-dose treatment of both Lasix and these other drugs may result such as cisplatin may be enhanced if Lasix is not given in lower doses and with

There are two major inherited forms of PKD, autosomal dominant PKD, and autosomal recessive PKD. in elevated serum levels of these drugs and may potentiate their toxicity as experience salicylate toxicity at lower doses because of competitive renal Edema associated with congestive heart failure (CHF), liver cirrhosis, and renal disease, including nephrotic syndrome20-80 mg PO once daily; may be increased by 20-40 mg q6-8hr; not to exceed 600 mg/dayAlternative: 20-40 mg IV/IM once; may be increased by 20 mg q2hr; individual dose not to exceed 200 mg/dose0.5-1 mg/kg (or 40 mg) IV over 1-2 minutes; may be increased to 80 mg if there is no adequate response within 1 hour;not to exceed 160-200 mg/dose Acute renal failure: 1-3 g/day may be necessary to attain desired response; avoid use in oliguric statesHepatic impairment: Monitor, especially with high dosagesUse for fluid retention refractory to thiazides or impaired renal functionInfants and children: 1-2 mg/kg IV/IM/PO once initially; increased by 1-2 mg/kg q6-8hr (PO) or 1 mg/kg q2hr (IV/IM); individual dose not to exceed 6 mg/kg Neonates (<28 days): 0.5-1 mg/kg IV/IM q8-24hr; individual dose not to exceed 2 mg/kg1-17 years: 0.5-2 mg/kg PO q24hr or q12hr; individual dose not to exceed 6 mg/kg/dose Excessive diuresis may cause dehydration and electrolyte loss in elderly; lower initial dosages and more gradual adjustments are recommended (eg, 10 mg/day PO)Increase in blood urea nitrogen (BUN) and loss of sodium may cause confusion in elderly; monitor renal function and electrolytes20 mg/day PO/IV/IM initially; increased slowly until desired response is obtainedIncreased patent ductus arteriosus during neonatal periodToxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, drug rash with eosinophila and systemic symptoms, acute generalized exanthematous pustulosis, exfoliative dermatitis, bullous pemphigoid purpura, pruritusAgent is potent diuretic that, if given in excessive amounts, may lead to profound diuresis with water and electrolyte depletionCareful medical supervision is required; dosing must be adjusted to patient's needsDocumented hypersensitivity to furosemide or sulfonamidesUse caution in systemic lupus erythematosus, liver disease, renal impairmentConcomitant ethacrynic acid therapy (increases risk of ototoxicity)Risks of fluid or electrolyte imbalance (including causing hyperglycemia, hyperuricemia, gout), hypotension, metabolic alkalosis, severe hyponatremia, severe hypokalemia, hepatic coma and precoma, hypovolemia (with or without hypotension)Do not commence therapy in hepatic coma and in electrolyte depletion until improvement is notedProlonged use in premature neonates may cause nephrocalcinosisEfficacy is diminished and risk of ototoxicity increased in patients with hypoproteinemia (associated with nephrotic syndrome); ototoxicity is associated with rapid injection, severe renal impairment, use of higher than recommended doses, concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugsTo prevent oliguria, reversible increases in BUN and creatinine, and azotemia, monitor fluid status and renal function; discontinue therapy if azotemia and oliguria occur during treatment of severe progressive renal diseaseFDA-approved product labeling for many medications have included a broad contraindication in patients with a prior allregic reaction to sulfonamides; however, recent studies have suggested that crossreactivity between antibiotic sulfonamides and nonantibiotic sulfonamides is unlikely to occurIn cirrhosis, electrolyte and acid/base imbalances may lead to hepatic encephalopathy; prior to initiation of therapy, correct electrolyte and acid/base imbalances, when hepatic coma is presentHigh doses (> 80 mg) of furosemide may inhibit binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by overall decrease in total thyroid hormone levelsIn patients at high risk for radiocontrast nephropathy furosemide can lead to higher incidence of deterioration in renal function after receiving radiocontrast compared to high-risk patients who received only intravenous hydration prior to receiving radiocontrastObserve patients regularly for possible occurrence of blood dyscrasias, liver or kidney damage, or other idiosyncratic reactionsCases of tinnitus and reversible or irreversible hearing impairment and deafness reportedHearing loss in neonates has been associated with use of furosemide injection; in premature neonates with respiratory distress syndrome, diuretic treatment with furosemide in the first few weeks of life may increase risk of persistent patent ductus arteriosus (PDA), possibly through a prostaglandin-E-mediated processExcessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patientsIncreases in blood glucose and alterations in glucose tolerance tests (with abnormalities of fasting and 2 hour postprandial sugar) have been observed, and rarely, precipitation of diabetes mellitus reportedPatients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine; these patients require careful monitoring, especially during initial stages of treatmentHypokalemia may develop with furosemide, especially with brisk diuresis, inadequate oral electrolyte intake, when cirrhosis is present, or during concomitant use of corticosteroids, ACTH, licorice in large amounts, or prolonged use of laxativesPregnancy category: C; treatment during pregnancy necessitates monitoring of fetal growth because of risk for higher fetal birth weightsLactation: Drug excreted into breast milk; use with caution; may inhibit lactationA: Generally acceptable.